secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001323885-25-000092
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook
-----------------------------------------------------------------

- Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).
- Net loss $6.2M, improved $1.8M YoY; adjusted EBITDA $15.4M, up $7.6M YoY.
- Basic/diluted EPS loss $0.13 vs $0.17; adjusted EPS loss $0.02 vs $0.17.
- Completed enrollment of 6,500 patients in the LeAAPS trial.
- Company raised full-year 2025 financial outlook.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388525000092/0001323885-25-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388525000092/atrc-20250729.htm
  HTML page:      https://secwatch.observer/filing/0001323885-25-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer